Boost for Mental Health Medicines R&D as COMPASS Pathways Joins the Psychiatry Consortium
Global mental health care company, COMPASS Pathways plc has joined the Psychiatry Consortium, bringing additional expertise and insights to the group.
A company dedicated to accelerating patient access to evidence-based innovation in mental health, COMPASS Pathways will further enhance the Consortium’s collective intelligence and reach.
Managed by Medicines Discovery Catapult, the Psychiatry Consortium comprises prominent players across industry, charities and academia, working together to develop and deliver a portfolio of innovative and collaborative projects, which focus on identifying and validating new therapeutic targets for psychiatric diseases.
Alongside the other members, COMPASS Pathways will support the Consortium’s core mission of addressing the unmet therapeutic needs of people living with mental health challenges.
Dr Gary Gilmour, Director of Preclinical Research, COMPASS Pathways, said:
“The scale of today’s mental health crisis is huge, and is getting bigger every day. The Psychiatry Consortium is bringing leading experts and resources together to speed up and reinvigorate the drug discovery process, and we are proud to be part of it. By working towards a common goal, we can bring evidence-based innovations to the people who need them, as quickly as possible.”
Prof. Chris Molloy, CEO, Medicines Discovery Catapult, said:
“We welcome COMPASS Pathways to the Psychiatry Consortium. The impact of poor mental health is felt in every community, hence a focus on improved treatments must be a necessary objective for healthcare and medicines providers. The Psychiatry Consortium represents a new, collaborative model of medicines R&D to target areas of unmet medical need in mental health, ‘head on’.
“The consortium combines multinational pharmaceutical drug discovery expertise, patient insight from leading medical research charities, and know-how of global research service providers, underpinned by the Catapult’s strategic guidance.
“Joining forces and resources ensures that the very best new ideas are pushed forward with industrial rigour and patient-focus. COMPASS Pathways brings unique new insight and perspective to the Psychiatry Consortium to help bring effective and safe new medicines to patients, faster.”
The ambition of the Psychiatry Consortium is to revitalise drug discovery in psychiatry disease by strengthening academic-industry collaborations. Collectively, the strategic partners aim to provide approximately £4 million in research funding over three years, to deliver up to 10 high-value drug discovery projects.
For more information on the Psychiatry Consortium, including details of all members, please visit the Psychiatry Consortium website.
